Uterus/ Endometrium Cancer Studies Currently Recruiting Participants at the University of Chicago Medicine Comprehensive Cancer Center

Study Number Title
09-123-B Long Term Database Collection for Endometrial Cancer
Select
10-627-A GOG 8013: Topoisomerase 2-Alpha (TOPO2A) Genomic Alterations and Immunohistochemical Expression As Well As Chromosome 17 Polysomy in Advanced or Recurrent Endometrial Carcinoma Treated with Anthracycline-Based Therapy
12-1157 Topoisomerase 2A (TOPO2A) Amplification/Overexpression and Other Predictive/Prognostic Markers in Women with Endometrial Cancer
Select
12-1419 GOG 277: A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) Versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma
Select
12-1650 GOG 275: A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-Day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
12-1767 Endometrial Cancer Survivorship: A Qualitative Approach to Understanding Healthy Lifestyle Change in African American Endometrial Cancer Survivors and Their Support Network
Select
IRB14-0081 Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Select
IRB14-0159 GOG 283: A Phase II Trial of DCTD Sponsored Dasatinib (NSC #732517 IND #120636) In Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression
Select
IRB14-0712 A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Atezolizumab (MPDL3280A) Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
Select
IRB13-1323 NCI 9322: A phase 2 study of XL184 (Cabozantinib) in recurrent or Metastatic Endometrial Cancer
Select
IRB14-1418 GOG Partners 3007: A Randomized Phase II Trial of Everolimus and Letrozole or Hormonal Therapy (Tamoxifen/ Medroxyprogesterone Acetate) in Women with Advanced, Persistent, or Recurrent Endometrial Carcinoma
Select
IRB15-1130 Phase I study of PD1 blockade by pembrolizumab with stereotactic body radiotherapy in advanced solid tumors

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.
Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT team